Four years and $145M+ later, Novo Nordisk hands back the rights to hormone growth deficiency test
After changing hands a couple of times, Aeterna Zentaris’ adult growth hormone deficiency (AGHD) test Macrilen is returning to its original developer as Novo Nordisk forfeits the rights.
Aeterna announced on Monday that the Danish pharma is returning the US and Canada rights, just four years after plunking down $145 million plus tiered royalties and an equity investment worth more than $36 million to secure the oral ghrelin agonist.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.